Endovascular bilateral pulmonary banding (ePAB)
Pt. noDCMProcedureFunctional regenerationFunctional Ross I–IV change (last follow-up) with ePAB + BLS
Age at diagnosis monthsAge at PAB monthsAge (months) after endoPAB
134.56IV to I
(4 years)
21.533–6IV to I
(14 months)
30.51.52IV to I
(8 months)
Endovascular bilateral pulmonary banding (ePAB)
Pt. noDCMProcedureFunctional regenerationFunctional Ross I–IV change (last follow-up) with ePAB + BLS
Age at diagnosis monthsAge at PAB monthsAge (months) after endoPAB
134.56IV to I
(4 years)
21.533–6IV to I
(14 months)
30.51.52IV to I
(8 months)

B, bisoprolol; DCM, dilated cardiomyopathy; ePAB, endoluminal pulmonary arterial banding; L, lisinopril; S, spironolactone.

Endovascular bilateral pulmonary banding (ePAB)
Pt. noDCMProcedureFunctional regenerationFunctional Ross I–IV change (last follow-up) with ePAB + BLS
Age at diagnosis monthsAge at PAB monthsAge (months) after endoPAB
134.56IV to I
(4 years)
21.533–6IV to I
(14 months)
30.51.52IV to I
(8 months)
Endovascular bilateral pulmonary banding (ePAB)
Pt. noDCMProcedureFunctional regenerationFunctional Ross I–IV change (last follow-up) with ePAB + BLS
Age at diagnosis monthsAge at PAB monthsAge (months) after endoPAB
134.56IV to I
(4 years)
21.533–6IV to I
(14 months)
30.51.52IV to I
(8 months)

B, bisoprolol; DCM, dilated cardiomyopathy; ePAB, endoluminal pulmonary arterial banding; L, lisinopril; S, spironolactone.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close